{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:18:04Z","timestamp":1788171484745,"version":"build-2803163510"},"reference-count":27,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy and safety of gepotidacin for the treatment of uncomplicated urogenital gonorrhea (uUGG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search of PubMed and Google Scholar (January 2010 to January 2026) was conducted using the terms gepotidacin and GSK2140944. Additional sources included conference abstracts, the manufacturer\u2019s website, and prescribing information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Relevant English-language studies evaluating the efficacy and safety of gepotidacin for uUGG were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>\n                      Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with a novel mechanism of action and potent activity against\n                      <jats:italic toggle=\"yes\">Neisseria gonorrhoeae<\/jats:italic>\n                      . In the phase 3 EAGLE-1 trial, gepotidacin demonstrated noninferiority to ceftriaxone plus azithromycin for uUGG treatment. It was generally well tolerated, with gastrointestinal adverse effects most commonly reported. Gepotidacin is administered as 3000 mg orally every 12 hours for 2 doses and is approved for adults and pediatric patients aged \u226512 years weighing \u226545 kg with limited or no alternative treatment options. Administration with food is recommended to reduce gastrointestinal adverse effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>Gepotidacin provides a new 2-dose oral option for uUGG treatment. Compared with ceftriaxone, the current drug of choice, oral administration may improve convenience and access. Similar to cefixime and zoliflodacin, its oral formulation may facilitate treatment while potentially reducing microbiome disruption compared with ceftriaxone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Gepotidacin is a promising oral antibiotic with a novel mechanism of action and demonstrated efficacy for uUGG treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261435593","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T04:36:05Z","timestamp":1775882165000},"page":"1012-1018","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6448-3879","authenticated-orcid":false,"given":"Spencer H.","family":"Durham","sequence":"first","affiliation":[{"name":"Pharmacy Practice, Auburn University Harrison College of Pharmacy, Huntsville, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7857-327X","authenticated-orcid":false,"given":"Amanda K.","family":"McAllister","sequence":"additional","affiliation":[{"name":"Auburn University Harrison College of Pharmacy, Huntsville, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Centers for Disease Control and Prevention. Sexually transmitted infections surveillance 2024 (Provisional). Updated September 24 2025. Accessed November 15 2025. https:\/\/www.cdc.gov\/sti-statistics\/annual\/index.html"},{"key":"e_1_3_2_3_2","unstructured":"World Health Organization. Sexually transmitted infections (STIs). Updated September 10 2025. Accessed November 15 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexually-transmitted-infections-(stis)"},{"key":"e_1_3_2_4_2","volume-title":"Antibiotic Resistance Threats in the United States, 2019","author":"CDC","year":"2019","unstructured":"CDC. Antibiotic Resistance Threats in the United States, 2019. U.S. Department of Health and Human Services, CDC; 2019."},{"key":"e_1_3_2_5_2","unstructured":"Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP): Gonorrhoea Treatment Optimization 2025 Report. World Health Organization; 2025."},{"key":"e_1_3_2_6_2","first-page":"332","article-title":"Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections","volume":"56","author":"CDC","year":"2007","unstructured":"CDC. Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007;56:332-336.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_7_2","unstructured":"CDC. Sexually transmitted disease surveillance 2013. US Department of Health and Human Services CDC; 2014. Accessed March 18 2026. https:\/\/www.cdc.gov\/std\/stats\/archive\/Surv2013-Print.pdf"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7004a1"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix249"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky548"},{"key":"e_1_3_2_11_2","unstructured":"Blujepa. Prescribing Information. Glaxosmithkline; 2025. Accessed December 12 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/218230s000lbl.pdf"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251343682"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02047-16"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01221-18"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy145"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00628-2"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2022-055518"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02196-7"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-016-0057-x"},{"issue":"7","key":"e_1_3_2_22_2","first-page":"773","article-title":"Factors determining the appropriateness of ceftriaxone usage at the emergency room of a university hospital in Thailand","volume":"96","author":"Phuphuakrat A","year":"2013","unstructured":"Phuphuakrat A, Kiertiburanakul S, Malathum K. Factors determining the appropriateness of ceftriaxone usage at the emergency room of a university hospital in Thailand. J Med Assoc Thai. 2013;96(7):773-781.","journal-title":"J Med Assoc Thai"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/1742-6723.12037"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75728-z"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10070779"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/8755122517720293"},{"key":"e_1_3_2_27_2","unstructured":"U.S Food and Drug Administration. FDA approves two oral therapies to treat gonorrhea. December 12 2025. Accessed March 6 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-two-oral-therapies-treat-gonorrhea"},{"key":"e_1_3_2_28_2","unstructured":"Nuzolvence (zoliflodacin). Prescribing Information. Innoviva Specialty Therapeutics; 2025. Accessed March 6 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/219491Orig1s000lbl.pdf"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261435593","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261435593","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261435593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:52:55Z","timestamp":1788169975000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261435593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10600280261435593"],"URL":"https:\/\/doi.org\/10.1177\/10600280261435593","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}